Export Ready — 

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

BACKGROUND: Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. This analysis reports benchmarks for clinical outcomes based on International Metastatic Ren...

Full description

Saved in:
Bibliographic Details
Published in:Clin Genitourin Cancer
Main Authors: Rini, Brian I, Hutson, Thomas E., Figlin, Robert A., Lechuga, Maria Josè, Valota, Olga, Serfass, Lucile, Rosbrook, Brad, Motzer, Robert J.
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690431/
https://ncbi.nlm.nih.gov/pubmed/29853320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.04.005
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items